Deutsche Bank Keeps a Buy Rating on Qiagen (QGEN)
In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Qiagen (QGEN). The company’s shares closed last Tuesday at $47.84.
According to TipRanks.com, Friedrichs is ranked #1890 out of 7491 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Qiagen with a $57.92 average price target, implying a 22.2% upside from current levels. In a report released today, Berenberg Bank also maintained a Buy rating on the stock with a EUR56.00 price target.
See today’s analyst top recommended stocks >>
Qiagen’s market cap is currently $10.85B and has a P/E ratio of 31.70. The company has a Price to Book ratio of -37.51.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Read More on QGEN: